Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On November 17, 2022, we reported on a preliminary assessment from the US Food and Drug Administration (FDA) that showed certain naloxone products may be approvable for nonprescription use.
The assessment
The FDA's Federal Register notice included a preliminary assessment that naloxone nasal spray (up to 4 mg) and naloxone autoinjector for intramuscular or subcutaneous use (up to 2 mg) may be approvable as safe and effective for nonprescription use for the prevention of overdose deaths.
"We need additional data such as product-specific data on the nonprescription user interface design, including packaging and labeling, to make a conclusive determination in this respect," wrote the FDA.
